Not checkedNot checked for notices yet.
RAS pathway targeted therapy in patients with DICER1-associated sarcomas
Lindy Zhang, Paige H. R. Mallinger, Serena Zhou and 12 more
npj Precision Oncology · 2025
doi:10.1038/s41698-025-01026-0 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
DICER1 -associated sarcomas commonly exhibit cooperating mutations involving RAS signaling pathways, but the efficacy of therapies that target these mutations is unknown. Here we report two children with DICER1 tumor predisposition who presented with DICER1 -associated sarcomas with cooperating, targetable mutations in HRAS or BRAF . Both had relapsed/progressed disease despite upfront multimodal therapy and were subsequently treated with molecularly targeted agents. In the first case, mutant BRAF became amplified after dual dabrafenib/trametinib therapy, presumably as a driver of acquired resistance. In the second case, a subclonal HRAS variant at diagnosis became the predominant clone at autopsy, suggesting its importance in therapy resistance. Together, these two cases provide molecular evidence of the significance of RAS/ERK signaling in DICER1 -driven tumorigenesis and highlight the potential for targeting these cooperating mutations.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.